gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Hepatitis A virus cellular receptor 1

TIMI
The protein encoded by this gene is a membrane receptor for both human hepatitis A virus (HHAV) and TIMD4. The encoded protein may be involved in the moderation of asthma and allergic diseases. The reference genome represents an allele that retains a MTTVP amino acid segment that confers protection against atopy in HHAV seropositive individuals. Three transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Mar 2010] (from NCBI)
Top mentioned proteins: CD45, HAD, AGE, CAN, Ami
Papers on TIMI
Cardiovascular Effects of Incretin-Based Therapies.
New
Baker et al., Farmington, United States. In Annu Rev Med, Feb 2016
This article reviews the most recent CV outcome trials of the DPP-4 inhibitors (SAVOR-TIMI 53, EXAMINE, and TECOS) as evidence that the incretin-based therapies have acceptable CV safety profiles for patients with T2DM.
Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
New
Tamburino et al., Catania, Italy. In Eur Heart J Acute Cardiovasc Care, Feb 2016
Compared with non-HPR patients, those with HPR had significantly lower rates of pre-PCI Thrombolysis in Myocardial Infarction (TIMI) flow grades 2 or 3 (51.1% vs. 32.5%,
Targeting myocardial reperfusion injuries with cyclosporine in the CIRCUS Trial - Pharmacological reasons for failure.
New
Pathak et al., Strasbourg, France. In Fundam Clin Pharmacol, Jan 2016
First, it could be explained by a limited diffusion of the drug in the area at risk, due to the only inclusion of patients with a TIMI 0 or 1 coronary blood flow in the anterior territory and the absence of collateral perfusion.
Dual pathway therapy in acute coronary syndrome.
Review
New
Zirlik et al., Freiburg, Germany. In J Thromb Thrombolysis, Jan 2016
In contrast, the ATLAS ACS2 TIMI-51 trial interrogating the oral factor Xa inhibitor rivaroxaban in a low dose regimen showed significant reduction of cardiovascular events as well as total mortality.
Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction.
New
Zhang et al., Xuzhou, China. In Eur Rev Med Pharmacol Sci, Dec 2015
PAR, thrombolysis in myocardial infarction (TIMI) flow, clinical outcomes and adverse reactions were compared between groups.
DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.
New
Paneni, Stockholm, Sweden. In Cardiovasc Diagn Ther, Dec 2015
Specifically, the use of dipeptidyl-peptidase-4 (DDP-4) inhibitors (DPP-4i) has recently raised a major safety concern owing to an increase of HF hospitalizations in SAVOR-TIMI 53 trial.
Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS.
Review
New
Sinha et al., Calcutta, India. In J Diabetes Res, Dec 2015
On the face value SAVOR TIMI and EXAMINE satisfied the primary composite CV end-points.
Lorcaserin Hcl for the treatment of obesity.
Review
New
Aronne et al., United States. In Expert Opin Pharmacother, Nov 2015
The results of the ongoing cardiovascular outcomes trial (CAMELLIA TIMI 61) will determine the role of lorcaserin in primary prevention of diabetes in overweight/obese individuals and its use in the high-risk population of patients with established cardiovascular disease or multiple cardiovascular risk factors.
On-treatment platelet reactivity: State of the art and perspectives.
Review
New
Giusti et al., Florence, Italy. In Vascul Pharmacol, Nov 2015
To overcome the limitation of clopidogrel, new antiplatelet agents (prasugrel and ticagrelor) were developed and the demonstration of their superiority over clopidogrel was obtained in the two randomized trials, TRITON TIMI 38 and PLATO.
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies.
Review
New
Kim et al., Puch'ŏn, South Korea. In Diabetes Metab J, Oct 2015
According to the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53) and EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE) trials, DPP4 inhibitors, including saxagliptin and alogliptin, did not appear to increase the risk of CV events in patients with type 2 diabetes and established CVD or high risk factors.
Long-term use of ticagrelor in patients with prior myocardial infarction.
New
Impact
PEGASUS-TIMI 54 Steering Committee and Investigators et al., Macao. In N Engl J Med, Jun 2015
The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding.
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
Impact
Steen et al., Auckland, New Zealand. In Jama, 2014
DESIGN, SETTING, AND PARTICIPANTS: SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial that randomized 13,026 participants within 30 days of hospitalization with an ACS (non-ST-elevation or ST-elevation myocardial infarction [MI]) at 868 sites in 36 countries.
Edoxaban versus warfarin in patients with atrial fibrillation.
Impact
ENGAGE AF-TIMI 48 Investigators et al., Warsaw, Poland. In N Engl J Med, 2013
(Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Impact
SAVOR-TIMI 53 Steering Committee and Investigators et al., Boston, United States. In N Engl J Med, 2013
(Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
Impact
ACCOAST Investigators et al., Paris, France. In N Engl J Med, 2013
The rate of the key safety end point of all Thrombolysis in Myocardial Infarction (TIMI) major bleeding episodes, whether related or not related to coronary-artery bypass grafting (CABG), through day 7 was increased with pretreatment (hazard ratio, 1.90; 95% CI, 1.19 to 3.02; P=0.006).
Lineage-specific evolution of T-cell immunoglobulin and mucin domain 1 gene in the primates.
GeneRIF
Kimura et al., Tokyo, Japan. In Immunogenetics, 2012
Data suggest that T-cell immunoglobulin domain and mucin domain containing protein 1 (TIM1) to be under positive natural selection in primates.
Association of Hepatitis A exposure and TIM-1 with childhood allergic asthma.
GeneRIF
Zhou et al., Chongqing, China. In J Asthma, 2012
the -416G>C polymorphism of the TIM-1 gene is associated with childhood allergic asthma.
Timeless preserves telomere length by promoting efficient DNA replication through human telomeres.
GeneRIF
Noguchi et al., Philadelphia, United States. In Cell Cycle, 2012
Timeless functions together with TRF1 to prevent fork collapse at telomere repeat DNA and ensure stable maintenance of telomere length and integrity.
Distinct role of matrix metalloproteinase-3 in kidney injury molecule-1 shedding by kidney proximal tubular epithelial cells.
GeneRIF
Leung et al., Hong Kong, Hong Kong. In Int J Biochem Cell Biol, 2012
in vitro and in vivo evidences suggest that MMP-3 plays an inductive role in KIM-1 shedding by PTEC
Polymorphisms of the TIM-1 gene are associated with rheumatoid arthritis in the Chinese Hui minority ethnic population.
GeneRIF
Wang et al., Yinchuan, China. In Genet Mol Res, 2011
-1637A>G and -232A>G polymorphisms of TIM-1 are associated with susceptibility to rheumatoid arthritis in the Chinese Hui population.
share on facebooktweetadd +1mail to friends